{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:26Z","timestamp":1790346686054,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ymthe.2024.03.017","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T22:43:26Z","timestamp":1710974606000},"page":"875-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chimeric oncolytic adenovirus to break away from neutralizing antibodies"],"prefix":"10.1016","volume":"32","author":[{"given":"Judit","family":"Sanchez Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Fudaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-241X","authenticated-orcid":false,"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.03.017_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic Viruses for Cancer Therapy: Barriers and\u00a0Recent Advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2024.03.017_bib2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.017_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.03.017_bib4","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.017_bib5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ymthe.2024.01.035","article-title":"Chimeric oncolytic adenovirus evades neutralizing antibodies from\u00a0human patients and exhibits enhanced anti-glioma efficacy in immunized mice","volume":"32","author":"Shin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.03.017_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","volume":"70","author":"Groeneveldt","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2024.03.017_bib7","article-title":"Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.03.017_bib8","article-title":"Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy","volume":"9","author":"Shin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.017_bib9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2016.67","article-title":"Predictive and Prognostic Clinical Variables in Cancer Patients\u00a0Treated With Adenoviral Oncolytic Immunotherapy","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.03.017_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.03.017_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/v14112327","article-title":"Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus","volume":"14","author":"Ding","year":"2022","journal-title":"Viruses"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:19:44Z","timestamp":1744449584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624001588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1525001624001588"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric oncolytic adenovirus to break away from neutralizing antibodies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}